말초신경자극기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 모달리티별, 용도별, 접속 방식별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)
Peripheral Nerve Stimulators Market Size, Share & Trends Analysis Report By Product, By Modality, By Application, By Connectivity, By End Use, By Region, And Segment Forecasts, 2025 - 2033
상품코드
:
1841945
리서치사
:
Grand View Research
발행일
:
2025년 09월
페이지 정보
:
영문 300 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
말초신경자극기 시장 요약
전 세계 말초신경자극기 시장 규모는 2024년에 2억 7,179만 달러로 추정되며 2033년에는 6억 8,030만 달러에 달할 것으로 예상되며, 2025년부터 2033년까지 10.89%의 CAGR로 성장할 것으로 예상됩니다.
만성 통증 질환의 유병률 증가, 최소침습적 및 비오피오이드 치료 선호도 증가, 신경 조절 기술의 지속적인 발전이 업계 성장의 주요 원동력이 되고 있습니다.
만성 통증 질환의 유병률 증가는 말초신경자극기 산업의 주요 촉진요인 중 하나입니다. 신경병증성 통증, 편두통, 수술 후 통증 등의 치료는 종종 장기적인 장애를 유발하지만, 오피오이드와 같은 기존 치료법은 중독의 위험이 있고 효과도 제한적입니다. 예를 들어, Brain Research UK가 발표한 최근 데이터에 따르면, 다음과 같은 사실과 통계는 영국의 신경 질환의 부담을 강조하고 있습니다:
목차 제1장 분석 방법·범위
제2장 주요 요약
제3장 말초신경자극기 시장 : 변수, 동향, 범위
시장 연관 전망
시장 역학
시장 성장 촉진요인 분석
시장 성장 억제요인 분석
시장 기회 분석
시장 과제 분석
말초신경자극기 시장 : 분석 툴
업계 분석 : Porter's Five Forces 분석
PESTEL 분석
제4장 말초신경자극기 시장 : 제품별 추정·동향 분석
부문 대시보드
세계의 말초신경자극기 시장 : 변동 분석, 제품별
세계의 말초신경자극기 시장 규모와 동향 분석 : 제품별(2021-2033년)
시스템
웨어러블/액세서리
제5장 말초신경자극기 시장 : 모달리티별 추정·동향 분석
부문 대시보드
세계의 말초신경자극기 시장 : 변동 분석, 모달리티별
세계의 말초신경자극기 시장 규모와 동향 분석 : 모달리티별(2021-2033년)
충전식
비충전식
제6장 말초신경자극기 시장 : 용도별 추정·동향 분석
부문 대시보드
세계의 말초신경자극기 시장 : 변동 분석, 용도별
세계의 말초신경자극기 시장 규모와 동향 분석 : 용도별(2021-2033년)
당뇨병성 말초신경병증 통증
만성적 근골격통
복합부위 통증 증후군(CRPS)
두통·편두통
기타
제7장 말초신경자극기 시장 : 접속 방식별 추정·동향 분석
부문 대시보드
세계의 말초신경자극기 시장 : 변동 분석, 접속 방식별
세계의 말초신경자극기 시장 규모와 동향 분석 : 접속 방식별(2021-2033년)
유선
무선
제8장 말초신경자극기 : 최종 용도별 추정·동향 분석
부문 대시보드
세계의 말초신경자극기 시장 : 변동 분석, 최종 용도별
세계의 말초신경자극기 시장 규모와 동향 분석 : 최종 용도별(2021-2033년)
병원·진료소
외래 수술 센터(ASC)
외래 수술 센터 : 시장 추정치·예측치(2021-2033년)
물리치료/재활 센터
물리치료/재활 센터 : 시장 추정치·예측치(2021-2033년)
기타
기타 : 시장 추정치·예측치(2021-2033년)
제9장 말초신경자극기 시장 : 지역별 추정·동향 분석
시장 대시보드 : 지역별
시장 규모 예측과 동향 분석(2021-2033년)
북미
유럽
영국
독일
프랑스
이탈리아
스페인
덴마크
스웨덴
노르웨이
아시아태평양
라틴아메리카
중동 및 아프리카
남아프리카공화국
사우디아라비아
아랍에미리트
쿠웨이트
제10장 경쟁 구도
최근 동향과 영향 분석 : 주요 시장 진입 기업별
기업/경쟁 분류
벤더 상황
주요 판매대리점 및 채널 파트너 리스트
주요 고객
세계의 주요 기업 : 시장 점유율 분석(2024년)
B. Braun SE
Nalu Medical, Inc.
Curonix LLC.
SPR
Vygon
AirLife
Neuspera Medical
AVNS
Mercury Medical
Medilogix
Anesthesia Associates, Inc.
Medtronic
Boston Scientific Corporation
Abbott
Bioventus
Checkpoint Surgical Inc.
NEURIMPULSE srl
Nervonik, Inc
Epineuron Technologies Inc.
히트맵 분석/기업 시장 상황 분석
시장 점유율 예측 분석 : 기업별(2024년)
기타 주요 기업 리스트
KSM
영문 목차
Peripheral Nerve Stimulators Market Summary
The global peripheral nerve stimulators market size was estimated at USD 271.79 million in 2024 and is projected to reach USD 680.30 million by 2033, growing at a CAGR of 10.89% from 2025 to 2033. The rising prevalence of chronic pain disorders, increasing preference for minimally invasive and non-opioid therapies, and continuous advancements in neuromodulation technologies are the primary driving factors contributing to the growth of the industry.
The rising prevalence of chronic pain disorders is one of the key driving factors of the peripheral nerve stimulators industry. Conditions like neuropathic pain, migraines, and post-surgical pain often cause long-term disability, while traditional treatments such as opioids carry risks of addiction and limited efficacy. For instance, according to recent data published by Brain Research UK, the following facts and statistics highlight the burden of neurological conditions in the UK:
Global Peripheral Nerve Stimulators Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global peripheral nerve stimulators market report based on product, modality, connectivity, application, end use, and region:
Product Outlook (Revenue, USD Million, 2021 - 2033)
Systems
Implantable
Non-implantable
Handheld
Others
Wearables/Accessories
Modality Outlook (Revenue, USD Million, 2021 - 2033)
Rechargeable
Non-rechargeable
Connectivity Outlook (Revenue, USD Million, 2021 - 2033)
Wired
Wireless
Application Outlook (Revenue, USD Million, 2021 - 2033)
Diabetic Peripheral Neuropathy Pain
Chronic Musculoskeletal Pain
Complex Regional Pain Syndrome (CRPS)
Headache and migraine disorders
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals and Clinics
Ambulatory Surgical Centers (ASCs)
Physiotherapy/Rehabilitation Centers
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Table of Contents Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product Type
1.1.2. Modality
1.1.3. Application
1.1.4. Connectivity
1.1.5. End-use
1.1.6. Regional scope
1.1.7. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR's internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Peripheral Nerve Stimulators Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising prevalence of chronic pain disorders
3.2.1.2. Growing preference for minimally invasive therapies
3.2.1.3. Opioid crisis and shift toward non-opioid pain management
3.2.1.4. Expanding applications beyond chronic pain
3.2.2. Market restraint analysis
3.2.2.1. High cost of devices and procedures
3.2.2.2. Risk of complications and device-related issues
3.2.3. Market opportunity analysis
3.2.3.1. Expansion into new indications
3.2.3.2. Adoption in outpatient & home-care settings
3.2.3.3. Rising demand for personalized pain management
3.2.4. Market challenge analysis
3.2.4.1. Competition from alternative therapies
3.2.4.2. Patient selection challenges
3.3. Peripheral Nerve Stimulators Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political & Legal Landscape
3.3.2.2. Economic and Social Landscape
3.3.2.3. Technological landscape
Chapter 4. Peripheral Nerve Stimulators Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Peripheral Nerve Stimulators Market Product Movement Analysis
4.3. Global Peripheral Nerve Stimulators Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Systems
4.4.1. Systems market estimates and forecasts for 2021 to 2033 (USD Million)
4.4.1.1. Implantable
4.4.1.1.1. Implantable market estimates and forecasts for 2021 to 2033 (USD Million)
4.4.1.2. Non-implantable
4.4.1.2.1. Non-implantable market estimates and forecasts for 2021 to 2033 (USD Million)
4.4.1.2.1.1. Handheld
4.4.1.2.1.1.1. Handheld market estimates and forecasts for 2021 to 2033 (USD Million)
4.4.1.2.1.2. Others
4.4.1.2.1.1.1. Handheld market estimates and forecasts for 2021 to 2033 (USD Million)
4.5. Wearables/Accessories
4.5.1. Wearables/Accessories market estimates and forecasts for 2021 to 2033 (USD Million)
Chapter 5. Peripheral Nerve Stimulators Market: Modality Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Peripheral Nerve Stimulators Market Modality Movement Analysis
5.3. Global Peripheral Nerve Stimulators Market Size & Trend Analysis, by Modality, 2021 to 2033 (USD Million)
5.4. Rechargeable
5.4.1. Rechargeables market estimates and forecasts for 2021 to 2033 (USD Million)
5.5. Non-Rechargeable
5.5.1. Non-rechargeable market estimates and forecasts for 2021 to 2033 (USD Million)
Chapter 6. Peripheral Nerve Stimulators Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Peripheral Nerve Stimulators Market Application Movement Analysis
6.3. Global Peripheral Nerve Stimulators Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Diabetic Peripheral Neuropathy Pain
6.4.1. Diabetic peripheral neuropathy pain market estimates and forecasts for 2021 to 2033 (USD Million)
6.5. Chronic Musculoskeletal Pain
6.5.1. Chronic musculoskeletal pain market estimates and forecasts for 2021 to 2033 (USD Million)
6.6. Complex Regional Pain Syndrome (CRPS)
6.6.1. Complex regional pain syndrome (CRPS) market estimates and forecasts for 2021 to 2033 (USD Million)
6.7. Headache and Migraine Disorders
6.7.1. Headache and migraine disorders market estimates and forecasts for 2021 to 2033 (USD Million)
6.8. Others
6.8.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)
Chapter 7. Peripheral Nerve Stimulators Market: Connectivity Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Global Peripheral Nerve Stimulators Market Connectivity Movement Analysis
7.3. Global Peripheral Nerve Stimulators Market Size & Trend Analysis, by Connectivity, 2021 to 2033 (USD Million)
7.4. Wired
7.4.1. Wired market estimates and forecasts for 2021 to 2033 (USD Million)
7.5. Wireless
7.5.1. Wireless market estimates and forecasts for 2021 to 2033 (USD Million)
Chapter 8. Peripheral Nerve Stimulators: End Use Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Global Peripheral Nerve Stimulators Market End Use Movement Analysis
8.3. Global Peripheral Nerve Stimulators Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
8.4. Hospitals and Clinics
8.4.1. Hospitals and Clinics market estimates and forecasts for 2021 to 2033 (USD Million)
8.5. Ambulatory Surgical Centers (ASCs)
8.5.1. Specialty clinics market estimates and forecasts for 2021 to 2033 (USD Million)
8.6. Physiotherapy/Rehabilitation Centers
8.6.1. Ambulatory surgery centers market estimates and forecasts for 2021 to 2033 (USD Million)
8.7. Others
8.7.1. Others market estimates and forecasts for 2021 to 2033 (USD Million)
Chapter 9. Peripheral Nerve Stimulators Market: Regional Estimates & Trend Analysis
9.1. Regional Dashboard
9.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
9.3. North America
9.3.1. Market estimates and forecast, 2021 - 2033 (Revenue, USD Million)
9.3.2. U.S.
9.3.2.1. Key country dynamics
9.3.2.2. Competitive scenario
9.3.2.3. Regulatory framework
9.3.2.4. Reimbursement scenario
9.3.2.5. U.S. market estimates and forecasts, 2021 - 2033
9.3.3. Canada
9.3.3.1. Key country dynamics
9.3.3.2. Competitive scenario
9.3.3.3. Regulatory framework
9.3.3.4. Reimbursement scenario
9.3.3.5. Canada market estimates and forecasts, 2021 - 2033
9.3.4. Mexico
9.3.4.1. Key country dynamics
9.3.4.2. Competitive scenario
9.3.4.3. Regulatory framework
9.3.4.4. Reimbursement scenario
9.3.4.5. Mexico market estimates and forecasts, 2021 - 2033
9.4. Europe
9.4.1. UK
9.4.1.1. Key country dynamics
9.4.1.2. Competitive scenario
9.4.1.3. Regulatory framework
9.4.1.4. Reimbursement scenario
9.4.1.5. UK market estimates and forecasts, 2021 - 2033
9.4.2. Germany
9.4.2.1. Key country dynamics
9.4.2.2. Competitive scenario
9.4.2.3. Regulatory framework
9.4.2.4. Reimbursement scenario
9.4.2.5. Germany market estimates and forecasts, 2021 - 2033
9.4.3. France
9.4.3.1. Key country dynamics
9.4.3.2. Competitive scenario
9.4.3.3. Regulatory framework
9.4.3.4. Reimbursement scenario
9.4.3.5. France market estimates and forecasts, 2021 - 2033
9.4.4. Italy
9.4.4.1. Key country dynamics
9.4.4.2. Competitive scenario
9.4.4.3. Regulatory framework
9.4.4.4. Reimbursement scenario
9.4.4.5. Italy market estimates and forecasts, 2021 - 2033
9.4.5. Spain
9.4.5.1. Key country dynamics
9.4.5.2. Competitive scenario
9.4.5.3. Regulatory framework
9.4.5.4. Reimbursement scenario
9.4.5.5. Spain market estimates and forecasts, 2021 - 2033
9.4.6. Denmark
9.4.6.1. Key country dynamics
9.4.6.2. Competitive scenario
9.4.6.3. Regulatory framework
9.4.6.4. Reimbursement scenario
9.4.6.5. Denmark market estimates and forecasts, 2021 - 2033
9.4.7. Sweden
9.4.7.1. Key country dynamics
9.4.7.2. Competitive scenario
9.4.7.3. Regulatory framework
9.4.7.4. Reimbursement scenario
9.4.7.5. Sweden market estimates and forecasts, 2021 - 2033
9.4.8. Norway
9.4.8.1. Key country dynamics
9.4.8.2. Competitive scenario
9.4.8.3. Regulatory framework
9.4.8.4. Reimbursement scenario
9.4.8.5. Norway market estimates and forecasts, 2021 - 2033
9.5. Asia Pacific
9.5.1. Japan
9.5.1.1. Key country dynamics
9.5.1.2. Competitive scenario
9.5.1.3. Regulatory framework
9.5.1.4. Reimbursement scenario
9.5.1.5. Japan market estimates and forecasts, 2021 - 2033
9.5.2. India
9.5.2.1. Key country dynamics
9.5.2.2. Competitive scenario
9.5.2.3. Regulatory framework
9.5.2.4. Reimbursement scenario
9.5.2.5. India market estimates and forecasts, 2021 - 2033
9.5.3. China
9.5.3.1. Key country dynamics
9.5.3.2. Competitive scenario
9.5.3.3. Regulatory framework
9.5.3.4. Reimbursement scenario
9.5.3.5. China market estimates and forecasts, 2021 - 2033
9.5.4. South Korea
9.5.4.1. Key country dynamics
9.5.4.2. Competitive scenario
9.5.4.3. Regulatory framework
9.5.4.4. Reimbursement scenario
9.5.4.5. South Korea market estimates and forecasts, 2021 - 2033
9.5.5. Australia
9.5.5.1. Key country dynamics
9.5.5.2. Competitive scenario
9.5.5.3. Regulatory framework
9.5.5.4. Reimbursement scenario
9.5.5.5. Australia market estimates and forecasts, 2021 - 2033
9.5.6. Thailand
9.5.6.1. Key country dynamics
9.5.6.2. Competitive scenario
9.5.6.3. Regulatory framework
9.5.6.4. Reimbursement scenario
9.5.6.5. Thailand market estimates and forecasts, 2021 - 2033
9.6. Latin America
9.6.1. Brazil
9.6.1.1. Key country dynamics
9.6.1.2. Competitive scenario
9.6.1.3. Regulatory framework
9.6.1.4. Reimbursement scenario
9.6.1.5. Brazil market estimates and forecasts, 2021 - 2033
9.6.2. Argentina
9.6.2.1. Key country dynamics
9.6.2.2. Competitive scenario
9.6.2.3. Regulatory framework
9.6.2.4. Reimbursement scenario
9.6.2.5. Argentina market estimates and forecasts, 2021 - 2033
9.7. MEA
9.7.1. South Africa
9.7.1.1. Key country dynamics
9.7.1.2. Competitive scenario
9.7.1.3. Regulatory framework
9.7.1.4. Reimbursement scenario
9.7.1.5. South Africa market estimates and forecasts, 2021 - 2033
9.7.2. Saudi Arabia
9.7.2.1. Key country dynamics
9.7.2.2. Competitive scenario
9.7.2.3. Regulatory framework
9.7.2.4. Reimbursement scenario
9.7.2.5. Saudi Arabia market estimates and forecasts, 2021 - 2033
9.7.3. UAE
9.7.3.1. Key country dynamics
9.7.3.2. Competitive scenario
9.7.3.3. Regulatory framework
9.7.3.4. Reimbursement scenario
9.7.3.5. UAE market estimates and forecasts, 2021 - 2033
9.7.4. Kuwait
9.7.4.1. Key country dynamics
9.7.4.2. Competitive scenario
9.7.4.3. Regulatory framework
9.7.4.4. Reimbursement scenario
9.7.4.5. Kuwait market estimates and forecasts, 2021 - 2033
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Global Key company market share analysis, 2024
10.3.4. B. Braun SE
10.3.4.1. Company overview
10.3.4.2. Financial performance
10.3.4.3. Product Type benchmarking
10.3.4.4. Strategic initiatives
10.3.5. Nalu Medical, Inc.
10.3.5.1. Company overview
10.3.5.2. Financial performance
10.3.5.3. Product Type benchmarking
10.3.5.4. Strategic initiatives
10.3.6. Curonix LLC.
10.3.6.1. Company overview
10.3.6.2. Financial performance
10.3.6.3. Product Type benchmarking
10.3.6.4. Strategic initiatives
10.3.7. SPR
10.3.7.1. Company overview
10.3.7.2. Financial performance
10.3.7.3. Product Type benchmarking
10.3.7.4. Strategic initiatives
10.3.8. Vygon
10.3.8.1. Company overview
10.3.8.2. Financial performance
10.3.8.3. Product Type benchmarking
10.3.8.4. Strategic initiatives
10.3.9. AirLife
10.3.9.1. Company overview
10.3.9.2. Financial performance
10.3.9.3. Product Type benchmarking
10.3.9.4. Strategic initiatives
10.3.10. Neuspera Medical
10.3.10.1. Company overview
10.3.10.2. Financial performance
10.3.10.3. Product Type benchmarking
10.3.10.4. Strategic initiatives
10.3.11. AVNS
10.3.11.1. Company overview
10.3.11.2. Financial performance
10.3.11.3. Product Type benchmarking
10.3.11.4. Strategic initiatives
10.3.12. Mercury Medical
10.3.12.1. Company overview
10.3.12.2. Financial performance
10.3.12.3. Product Type benchmarking
10.3.12.4. Strategic initiatives
10.3.13. Medilogix
10.3.13.1. Company overview
10.3.13.2. Financial performance
10.3.13.3. Product Type benchmarking
10.3.13.4. Strategic initiatives
10.3.14. Anesthesia Associates, Inc.
10.3.14.1. Company overview
10.3.14.2. Financial performance
10.3.14.3. Product Type benchmarking
10.3.14.4. Strategic initiatives
10.3.15. Medtronic
10.3.15.1. Company overview
10.3.15.2. Financial performance
10.3.15.3. Product Type benchmarking
10.3.15.4. Strategic initiatives
10.3.16. Boston Scientific Corporation
10.3.16.1. Company overview
10.3.16.2. Financial performance
10.3.16.3. Product Type benchmarking
10.3.16.4. Strategic initiatives
10.3.17. Abbott
10.3.17.1. Company overview
10.3.17.2. Financial performance
10.3.17.3. Product Type benchmarking
10.3.17.4. Strategic initiatives
10.3.18. Bioventus
10.3.18.1. Company overview
10.3.18.2. Financial performance
10.3.18.3. Product Type benchmarking
10.3.18.4. Strategic initiatives
10.3.19. Checkpoint Surgical Inc.
10.3.19.1. Company overview
10.3.19.2. Financial performance
10.3.19.3. Product Type benchmarking
10.3.19.4. Strategic initiatives
10.3.20. NEURIMPULSE s.r.l.
10.3.20.1. Company overview
10.3.20.2. Financial performance
10.3.20.3. Product Type benchmarking
10.3.20.4. Strategic initiatives
10.3.21. Nervonik, Inc
10.3.21.1. Company overview
10.3.21.2. Financial performance
10.3.21.3. Product Type benchmarking
10.3.21.4. Strategic initiatives
10.3.22. Epineuron Technologies Inc.
10.3.22.1. Company overview
10.3.22.2. Financial performance
10.3.22.3. Product Type benchmarking
10.3.22.4. Strategic initiatives
10.4. Heat Map Analysis/ Company Market Position Analysis
10.5. Estimated Company Market Share Analysis, 2024
10.6. List of Other Key Market Players
관련자료
